Pigmented villonodular synovitis is the noncancerous disease in which abnormal growth of tissue occurs that lines the joints and tendons. Pigmented villonodular synovitis is categorized into two types, diffuse form and local or nodular form. The disease can be symptomatized by locking of joints, limitation of movements, and pain. In some cases, degradation of joint structure is observed. The cause of the disease is still unknown. Pigmented villonodular synovitis can be diagnosed by certain imaging techniques such as magnetic resonance imaging, computed tomography, and X-ray. Five Prime Therapeutics, Inc. is in the process of developing FPA008 as a colony stimulating factor receptor antagonist for the treatment of pigmented villonodular synovitis. Novartis AG is in the process of developing MCS110 as a macrophage colony stimulating factor inhibitor for the treatment of pigmented villonodular synovitis. Some of the companies having the pipeline of pigmented villonodular synovitis include Five Prime Therapeutics, Inc., Novartis AG, and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.